• The Eyes Offer A ‘Promising Window’ Into Brain Pathology

    Dec 01 | Diagnostics World News | The eyes could be easily and inexpensively imaged to reveal the presence of neurodegenerative diseases potentially years before telltale clinical signs, suggests a growing body of research. More
  • Microneedle-Based Patch Showcases Diagnostic Potential Of Interstitial Fluid

    Nov 24 | Diagnostics World News | A pair of researchers at Rice University have developed a disposable, microneedle-based biosensing platform capable of detecting malaria infection from protein biomarkers in dermal interstitial fluid. The system not only eliminates the need for finger pricks or blood draws, but also requires no manual processing and has no electronic components—making it potentially well-suited to resource-limited settings, as a point-of-care test performed at doctors’ offices and health clinics, and as a screening tool for home use by the general public. More
  • Saliva-Based Antibody Tests, Lung Ultrasounds for Diagnosis, Successful University Testing Strategy: COVID-19 Updates

    Nov 20 | Diagnostics World News I Blood biomarkers for detection of brain injury, MRS shows white matter changes, new multiplex SARS-CoV-2 test, diaphragmatic fibrosis associated with severe COVID-19, and high-dose anticoagulants show no clear benefits. Plus: Social isolation linked to hypertension, children mount antibodies without detection of virus, and a call for more efficient and adaptive testing measures. More
  • FIT Nearly Perfect At Ruling Out Colon Cancer In Symptomatic Individuals

    Nov 19 | Diagnostics World News | In the U.K., it has become common practice to routinely screen people for colon cancer using a fecal immunochemical test (FIT) that measures the level of blood in the stool as opposed to going straight to a colonoscopy—long the gold standard in the U.S. Now, there is also convincing evidence that an FIT should be the first line of investigation for patients presenting with symptoms suspicious of colon cancer, as well. More
  • Robotics and Magnetic Fields Could Improve Quality, Cost And Patient Satisfaction With Much-Dreaded Colonoscopy

    Nov 17 | Diagnostics World News | By making colonoscopies semi-autonomous, a global team of researchers hopes to eliminate some of the key drawbacks of the procedure that have made it highly unpopular with patients. More
  • CRISPR Diagnostics, A Plan for Reagent Shortages, Community Testing: COVID-19 Updates

    Nov 13 | Diagnostics World News | Stanford’s CRISPR-on-a-chip diagnostic, new diagnostic kit with DIY reagents, and recommendations to boost UK testing services. Plus, Oxford and Thermo Fisher join forces, Massachusetts school district plans weekly COVID-19 surveillance, and a new antibody test from EUROIMMUN. More
  • Test Strip Approach To Real-Time Cancer Tracking Moving Into Trials

    Nov 11 | Diagnostics World NewsPhysicians could use a diagnostic device to aid clinical decision-making for patients with cancer and chronic diseases at the point of care (POC)—be that in the home, doctor’s office, or hospital emergency department. More
  • Fall News, Updates From Mammoth Biosciences, Rady Children’s, Genomenon, New England Biolabs, More

    Nov 10 | Diagnostics World News | New products, collaborations and deployments from the past two months from Mammoth Biosciences, Scopio Labs, Caris Life Sciences, Rady Children’s, Genomenon, Thirona, the Society to Improve Diagnosis in Medicine, and more. More
  • SmartWatch Predicts SARS-CoV-2 Infection, Skin Reveals ‘Long Haulers’, Seven Forms Identified: COVID-19 Updates

    Nov 06 | Diagnostics World News I Red marrow main target, increase in STIs amid lockdown, Dante Labs to offer Fluidigm’s saliva-based test, COVID-19 worsens tinnitus, few SNFs have fast test result turnaround time, University of Illinois creates successful test and trace program, yearlong study will determine seropositivity in frontline workers, myocarditis not as common as suspected, PerkinElmer receives EUA for pooled sample testing, and viral load determines outcomes with COVID-19 pneumonia. Plus: Twenty percent experience GI symptoms, 1.7 million New Yorkers infected, lung damage found in ‘long COVID’, unique case infectious for 70 days, and delirium early symptom in elderly. More
  • Organ-On-A-Chip Model For Monitoring Side Effects Of Chemotherapy

    Nov 05 | Diagnostics World News | An international team of researchers has demonstrated that an organ-on-a-chip model can accurately measure the effects of a chemotherapeutic on breast cancer tissue and simultaneously identify the unintended side effects on healthy heart tissue. More
View more articles

 
DXX-Industry-spotlight

Acrobiosystems

Antigens & Antibodies for SARS-CoV-2 Diagnostic Kit Development

ACROBiosystems team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of high-quality antigen and antibody reagents to support the development of the diagnostic kits. The products include the high quality S trimer, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity tested on several platforms.

Click to learn more about ACRO’s hot matched antibody pairs and antigens.

DXX-Industry-spotlight

2020 Global Coronavirus Diagnostics Market


The report presents a detailed analysis of the Coronavirus diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Coronavirus definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: Hospitals, Commercial/Private Labs, Physician Offices and Public Health Labs.

Global Molecular Diagnostics Partnering 2014-2019: Deal trends, players, financials and forecasts


The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals. The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyze and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the Molecular Diagnostics partnering field; both the leading deal values and most active Molecular Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic deal making market.